Ceribell, Inc.

CBLL· Nasdaq· Electromedical & Electrotherapeutic Apparatus

Market cap
–
P/FCF
–
EV/Sales
–
FCF margin
-46.7%
ROIC, 5 yr avg
–
Revenue, 5 yr CAGR
–
We record prices for the companies we cover; CBLL is not one of them yet.

Company statistics

From the 10-Ks, computed in code · point at a figure for its formula

Profile · FY2025

Market cap
–
Enterprise value
–
Diluted shares
36.5M
Revenue
$89.1M
Free cash flow
-$41.6M
Owner earnings
-$53.8M

Valuation · FY2025

P/E
–
P/FCF
–
P/Owner earnings
–
EV/Sales
–
EV/FCF
–
P/B
–

Margins · FY2025

Gross
87.9%
Operating
-65.6%
Net
-60.0%
Free cash flow
-46.7%
Owner earnings
-60.4%
Stock pay
13.7%

Returns

ROIC, FY2025
–
ROIC, 5 yr avg
–
ROE, FY2025
-34.4%
ROE, 5 yr avg
–

Growth (CAGR)

Revenue, 3 yr
–
Revenue, 5 yr
–
Revenue, 2 yr
40.3%
Diluted EPS, 3 yr
–
Diluted EPS, 5 yr
–
Diluted EPS, 2 yr
–
Free cash flow, 3 yr
–
Free cash flow, 5 yr
–
Free cash flow, 2 yr
–

Financial health · FY2025

Cash and investments
$159.3M
Total debt
–
Net cash
–
Debt/Equity
–
Debt/FCF
–

Shareholder returns · FY2025

Dividend yield
–
Payout ratio
–
Buyback yield
–
Shareholder yield
–
Share count, 5 yr
–

Financials: ten years from the 10-Ks

Reported numbers open their filing · computed ones show the formula · ˢ split-adjusted

Revenue

$89.1M

+40.3% a year over 2 years

FY2023: Revenue $45.2MFY2024: Revenue $65.4MFY2025: Revenue $89.1M
FY2023FY2025

Margins

Gross87.9%Operating-65.6%Net-60.0%

FY2025

FY2023: Gross 84.4%, Operating -66.4%, Net -65.1%FY2024: Gross 86.7%, Operating -60.7%, Net -61.8%FY2025: Gross 87.9%, Operating -65.6%, Net -60.0%
FY2023FY2025

Free cash flow and owner earnings

Free cash flow-$41.6MOwner earnings-$53.8M

FY2025

FY2023: Free cash flow -$30.1M, Owner earnings -$32.8MFY2024: Free cash flow -$36.4M, Owner earnings -$41.8MFY2025: Free cash flow -$41.6M, Owner earnings -$53.8M
FY2023FY2025

Diluted shares

36.5M

+589.0% over 2 years, net dilution

FY2023: Diluted shares 5.3MFY2024: Diluted shares 11.9MFY2025: Diluted shares 36.5M
FY2023FY2025

Every figure, year by year

Fiscal yearFY2023FY2024FY2025
The business
Revenue$45.2M$65.4M$89.1M
Revenue growth–44.7%36.1%
Gross margin84.4%86.7%87.9%
Operating margin-66.4%-60.7%-65.6%
Net income-$29.5M-$40.5M-$53.4M
Net margin-65.1%-61.8%-60.0%
Diluted EPS$-5.56$-3.39$-1.46
Return on invested capital?–––
Cash
Operating cash flow-$29.2M-$35.0M-$40.8M
Capital expenditure$983.0K$1.3M$767.0K
Free cash flow-$30.1M-$36.4M-$41.6M
Stock-based compensation$2.7M$5.4M$12.2M
Owner earnings?-$32.8M-$41.8M-$53.8M
Free cash flow per share$-5.68$-3.04$-1.14
Capital allocation
Dividends paid–––
Share repurchases–––
Diluted shares5.3M11.9M36.5M
Share count change?–125.3%205.8%
Balance sheet
Cash and equivalents$34.5M$194.4M$40.5M
Short-term investments––$118.8M
Total debt–––
Net debt–––
Shareholders' equity-$112.3M$191.2M$155.3M

Latest filings

All on EDGAR
2026-08-1010-QQuarterly report
2026-08-108-KEarnings release
2026-05-1110-QQuarterly report
2026-05-118-KEarnings release
2026-04-20DEF 14AProxy statement
2026-02-2410-KAnnual report
2026-02-248-KEarnings release
2025-11-0410-QQuarterly report
2025-11-048-KEarnings release
2025-08-0510-QQuarterly report

More from our coverage

All coverage